

With so much COVID-19 data, why didn't we have better information about the pandemic?

DONAHUE | CREIGHTON ID SYMPOSIUM | 4.22.23

NEBRASKA
Good Life. Great Mission.
DEPT. OF HEALTH AND HUMAN SERVICES

DIVISION OF
PUBLIC HEALTH

1

NEEDS

Move & join large amounts of data quickly
Streamline everyday work
System ready for *pandemic era*

2

DATA SILOS & ECPI

MOVE & JOIN LARGE AMOUNTS OF DATA QUICKLY


3

TRADITIONAL PATH




4


4




5




6




7



8



9



10

TRADITIONAL PATH & UNMET NEEDS



11

NEBRASKA
Good Life. Great Mission. DIVISION OF
PUBLIC HEALTH

11

“...the pandemic isn’t what we normally do.”




We NEED to be able to meet every unmet need encountered throughout the pandemic

12

NEBRASKA
Good Life. Great Mission. DIVISION OF
PUBLIC HEALTH

12




13

Data NEXUS solar system




14


14




15




16



17



18



19

CHOOSE TODAY!

Get your booster vaccination against COVID-19 at your local pharmacy, doctor's office, or health dept.

VACCINATED WITHOUT UPDATED BOOSTER	VACCINATED WITH UPDATED BOOSTER
2x	17x
LOWER RISK OF DEATH	LOWER RISK OF DEATH

Over the last 20 weeks, people who were vaccinated **without an updated booster** were **2X** less likely to die from COVID-19 and people who were vaccinated **with an updated booster** were **17X** less likely to die from COVID-19 compared with people who were not vaccinated.

About the Analysis
The 20-week (Sept 01, 2022, to Jan 28, 2023) period was considered in the analysis as bivalent vaccines were approved on September 1, 2022.
Records having immunosuppressive conditions along with COVID-19 were excluded from the analysis.
Vaccination Data: Obtained from Nebraska state immunization information system (NEISIS)
Death Data: Obtained from Nebraska vital records death certificate data.
Incidence Rate Ratios (IRRs) for vaccinated without an updated booster for the past twenty weeks were calculated by dividing the average weekly incidence rates among the unvaccinated population by that among the population vaccinated without an updated booster. IRRs for those vaccinated with an updated booster for the past twenty weeks were calculated by dividing the average weekly incidence rates among the unvaccinated population by that among the population vaccinated with an updated booster.
Vaccine effectiveness was calculated based on the formula $VE = 1 - \text{Rate vaccinated} / \text{Rate unvaccinated}$
Age-adjusted IRRs were calculated by $IRR = 1 / (1 - \text{Age-adjusted VE})$

NEBRASKA
Good Life. Great Mission.
DEPT. OF HEALTH AND HUMAN SERVICES

Authors: Sai Paritala and Yi Du

20

20



How well does infection-induced immunity work?

How long does it last?

How well does it protect against infection, hospitalization, and death?

Does it prevent long-COVID-19 or complications like MIS?

How well does cross-variant immunity work?

How vulnerable are we to another big surge?

21



We have vaccine effectiveness but what about nuance?

How long do vaccines work?

Against infection, hospitalization, and death?

How does effectiveness differ per variant?

Is there one brand that's better?

What boosting timeline is most effectiveness?

Are these answers different across age groups, races, ethnicities, medical comorbidities, or rural/urban residence?


22



What about antiviral effectiveness

How well does nirmatrelvir-ritonavir work IN Nebraska?
Who is accessing it and where are the missed opportunities?


23



Death certificate data, not hospitalization data

24

24



25

AUTOMATED

REALTIME

COMPLETE

IDENTIFIABLE

FLEXIBLE

26

DIVISION OF
PUBLIC HEALTH

26

	NHA
AUTOMATED	N
REALTIME	N
COMPLETE	Y
IDENTIFIABLE	Y
FLEXIBLE	Y

27

NEBRASKA
Good Life. Great Mission.

DIVISION OF
PUBLIC HEALTH

27

	NHA	JUVARE
AUTOMATED	N	N
REALTIME	N	Y
COMPLETE	Y	N
IDENTIFIABLE	Y	N
FLEXIBLE	Y	N

28

NEBRASKA
Good Life. Great Mission.

DIVISION OF
PUBLIC HEALTH

28

	NHA	JUVARE	HHS PROTECT
AUTOMATED	N	N	N
REALTIME	N	Y	Y
COMPLETE	Y	N	Y
IDENTIFIABLE	Y	N	N
FLEXIBLE	Y	N	N

29

NEBRASKA
Good Life. Great Mission.

DIVISION OF
PUBLIC HEALTH

29

	NHA	JUVARE	HHS PROTECT	ECR
AUTOMATED	N	N	N	Y
REALTIME	N	Y	Y	Y
COMPLETE	Y	N	Y	N
IDENTIFIABLE	Y	N	N	Y
FLEXIBLE	Y	N	N	N

30

NEBRASKA
Good Life. Great Mission.

DIVISION OF
PUBLIC HEALTH

30

	NHA	JUVARE	HHS PROTECT	ECR	HIE
AUTOMATED	N	N	N	Y	Y
REALTIME	N	Y	Y	Y	Y
COMPLETE	Y	N	Y	N	N
IDENTIFIABLE	Y	N	N	Y	Y
FLEXIBLE	Y	N	N	N	Y

31

NEBRASKA
Good Life. Great Mission.

DIVISION OF
PUBLIC HEALTH

31

	NHA	JUVARE	HHS PROTECT	ECR	HIE
AUTOMATED	Y	N	N	Y	Y
REALTIME	Y	?	Y	Y	Y
COMPLETE	Y	?	Y	N	N
IDENTIFIABLE	Y	?	N	Y	Y
FLEXIBLE	Y	N	N	N	Y

32

NEBRASKA
Good Life. Great Mission.

DIVISION OF
PUBLIC HEALTH

32

FRAMEWORK



National
COVID
Cohort
Collaborative


<https://tracs.unc.edu/index.php/news/1668-national-covid-cohort-collaborative>

33

MODERN TOOLS

STREAMLINE EVERYDAY WORK

34



35




36



37

NEBRASKA NATIONAL GUARD COVID-19 TESTING

Figure 1: Frequency of symptoms by lab status in REDCap training dataset



38

38

Realtime AOE case-control identified LOS/LOT as strongest predictors of COVID-19 infection, prior to national recognition

Table 4: Odds ratios of significant ($p<0.05$) symptoms and symptom combinations derived from logistic regression analysis

Symptom/Combination	Odds Ratio	Wald 95% Confidence Intervals	
Loss of Smell	10.14	6.07	16.94
Loss of Taste	6.91	4.35	10.99
Fever/Chills	6.57	5.30	8.13
Sore Throat*Loss of Taste*Loss of Smell	5.92	2.10	16.69
Fever/Chills*Loss of Smell*Fatigue	5.16	2.10	12.70
Loss of Smell*Diarrhea	4.17	1.57	11.08
Fever/Chills*Cough*Congestion	3.64	1.80	7.35
Cough	3.47	2.89	4.16
Fever/Chills*Runny Nose*Loss of Taste	3.38	1.15	9.91
Cough*Sore Throat*Loss of Smell	3.38	1.36	8.41
Sore Throat*Loss of Taste*Diarrhea	3.37	1.21	9.39
Fever/Chills*Shortness of Breath*Sore Throat	2.91	1.37	6.18
Congestion	2.76	1.91	3.98
Sore Throat*Runny Nose*Congestion	2.32	1.13	4.75
Shortness of Breath*Loss of Taste	1.94	1.11	3.38
Sore Throat	1.56	1.23	1.99

39

39

Realtime AOE case-control identified LOS/LOT as strongest predictors of COVID-19 infection, prior to national recognition

Table 4: Odds ratios of significant ($p<0.05$) symptoms and symptom combinations derived from logistic regression analysis

Symptom/Combination	Odds Ratio	Wald 95% Confidence Intervals	
Loss of Smell	10.14	6.07	16.94
Loss of Taste	6.91	4.35	10.99
Fever/Chills	6.57	5.30	8.13
Sore Throat*Loss of Taste*Loss of Smell	5.92	2.10	16.69
Fever/Chills*Loss of Smell*Fatigue	5.16	2.10	12.70
Loss of Smell*Diarrhea	4.17	1.57	11.08
Fever/Chills*Cough*Congestion	3.64	1.80	7.35
Cough	3.47	2.89	4.16
Fever/Chills*Runny Nose*Loss of Taste	3.38	1.15	9.91
Cough*Sore Throat*Loss of Smell	3.38	1.36	8.41
Sore Throat*Loss of Taste*Diarrhea	3.37	1.21	9.39
Fever/Chills*Shortness of Breath*Sore Throat	2.91	1.37	6.18
Congestion	2.76	1.91	3.98
Sore Throat*Runny Nose*Congestion	2.32	1.13	4.75
Shortness of Breath*Loss of Taste	1.94	1.11	3.38
Sore Throat	1.56	1.23	1.99

Built outside of existing disease surveillance & case management system due to inflexibility and absence of needed tools

40

40



41

Ebola active monitoring: borrowed from COVID-19 & highly pathogenic avian influenza (HPAI)

Intake						Day 1		Day 2		Day 3		
Intake	Avianflu	COVID-19	Monkeypox	Ebola Risk Assessment	Monitoring Enrollment	Daily Symptom Review	Daily Symptom Review X2	Daily Symptom Review	Daily Symptom Review X2	Daily Symptom Review	Daily Symptom Review X2	Daily Symptom Review

42

42

Ebola active monitoring: borrowed from COVID-19 & highly pathogenic avian influenza (HPAI)

Intake						Day 1		Day 2		Day 3		
Intake	Avianflu	COVID-19	Monkeypox	Ebola Risk Assessment	Monitoring Enrollment	Daily Symptom Review	Daily Symptom Review X2	Daily Symptom Review	Daily Symptom Review X2	Daily Symptom Review	Daily Symptom Review X2	Daily Symptom Review

Built outside of existing disease surveillance & case management system due to inflexibility and absence of needed tools

43

43

CASE



PROSPECTIVE &
RETROSPECTIVE
CONTACT TRACING



POSITIVE LAB REPORTS



QUARANTINE/ISOLATION

CLUSTER MAPPING

44

Traditional cluster mapping (Powerpoint, NE)

Information current as of 7/22/2021

- Primary Contact/Attended Event
- Secondary Contacts / Contact with Person From Event
- Tertiary Contacts / Contact with Secondary Contact
- Partially Vaccinated
- Fully Vaccinated
- Not Confirmed Lab Case
- Δ+ Delta Positive
- ICU / Vent



45

45

Traditional cluster mapping (Excel, NE)

Information current as of 7/22/2021

- Primary Contact/Attended Event
- Secondary Contacts / Contact with Person From Event

Public Health Reports



Impact Factor: 3.117 / 5-Year Impact Factor: 3.268

[JOURNAL HOMEPAGE](#)

[SUBMIT PAPER](#)

Restricted access | Research article | First published online September 16, 2022

Outbreak of SARS-CoV-2 B.1.617.2 (Delta Variant) in a Youth Camp Associated With Community Spread, Nebraska, June–July 2021

[Julia \(He\) Bai, MPH](#) [Suzanne Phinney, RN](#) [Kathleen Angell, MPH](#) [Brandon Grimm, PhD, MPH](#) [Bryan Tegomoh, MD, MPH](#) [Jonathan Figliomeni, MHA](#) [Baha Abdalhamid, MD, PhD](#) [Ali S. Khan, MD, MPH, MBA](#) [Matthew Donahue, MD](#) [David M. Brett-Major, MD, MPH](#) and [Laura McDougall, MS](#) [View all authors and affiliations](#)

OnlineFirst | <https://doi.org/10.1177/00333549221123582>



46

46

Traditional cluster mapping (Powerpoint, NE)

Built outside of existing disease surveillance & case management system due to inflexibility and absence of needed tools

Information current as of 7/22/2021

- Primary Contact/Attended Event
- Secondary Contacts / Contact with Person From Event
- Tertiary Contacts / Contact with Secondary Contact
- Partially Vaccinated
- Fully Vaccinated
- Not Confirmed Lab Case
- Δ+ Delta Positive
- ICU / Vent



47

47


Traditional cluster mapping (Go.Data, WHO)




- **Geospatial map:** Uses the mapping servers configured during outbreak setup to transpose transition chains on a geographic map.

48

48




49



50


50

LINEAGE IDENTIFICATIONS




51


CLUSTER MAPPING WITH GENOMICS




52



53



54




55


ONE SYSTEM

SYSTEM READY FOR THE NEXT PANDEMIC ERA

56



57



58

DONAHUE | EPI UPDATES | 10.11.22



EBOLA
SITREP



MONKEYPOX
Genomic epidemiology



COVID-19
Bivalent VE

59

59

“...the pandemic isn't what we normally do.”

DONAHUE | EPI UPDATES | 10.11.22



EBOLA
SITREP



MONKEYPOX
Genomic epidemiology



COVID-19
Bivalent VE

Ready for *pandemic era*

We **NEED** to be able to
meet every unmet need
encountered throughout
the pandemic

60

60



THANK YOU

DIVISION OF PUBLIC HEALTH

NEBRASKA
Good Life. Great Mission.
DEPT. OF HEALTH AND HUMAN SERVICES

MATTHEW DONAHUE, MD
matthew.donahue@nebraska.gov